Cover Image
市場調查報告書

慢性淋巴性白血病治療藥的全球市場:2015-2019年

Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 336913
出版日期 內容資訊 英文 87 Pages
訂單完成後即時交付
價格
Back to Top
慢性淋巴性白血病治療藥的全球市場:2015-2019年 Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019
出版日期: 2015年08月05日 內容資訊: 英文 87 Pages
簡介

慢性淋巴性白血病是淋巴球過剩增殖的惡性疾病,可知首先引起B淋巴球障礙,之後恐怕在體內其他部分擴大。白血病形成癌症細胞的速度慢,多在發展後期發現。晚期惡性腫瘤擴散到脾臟和肝臟,淋巴節,不過進度不統一而難以預見。症狀有淋巴節腫,疲勞感,發熱,感染疾病,肋骨下疼痛,體重降低等。治療有放射線、類固醇、化療、標靶治療、移植 (骨髓和幹細胞) 、脾臟摘出手術等。慢性淋巴性白血病治療藥的全球市場今後至2019年期間,預計以18.52%的年複合成長率擴大。

本報告以慢性淋巴性白血病治療藥的全球市場為焦點,提供2015-2019年的期間、其概況及供需規模變遷的考察、預測、市場發展趨勢、推動要素、課題、主要企業簡介等最新分析資訊彙整。

第1章 摘要整理

第2章 簡稱一覽

第3章 報告的範圍

  • 市場概要
  • 產品結構

第4章 產品簡介

  • Gazyva/Gazyvaro
  • MabThera/Rituxan
  • Arzerra
  • Treanda

第5章 市場調查方法

  • 市場調查流程
  • 取材方式

第6章 疾病概要

  • 疾病的理解
  • 慢性淋巴性白血病的種類
  • 症狀
  • 進展階段
  • 流行病學
  • 管理
  • 經濟負擔

第7章 簡介

第8章 市場環境

  • 市場概要
  • 市場規模及預測
  • 波特的五力分析

第9章 開發平台組合

  • 代表性開發平台分子相關的重要資訊
    • RG 105 SC劑型
    • Obinutuzumab/ Venetoclax
    • RG 7596 (Polatuzumab vedotin)
    • RG 7601 (Venetoclax)

第10章 市場區隔 - 各給藥途徑

  • 口服給藥
  • 非口服給藥

第11章 市場區隔 - 各分子形態

  • 小分子
  • 生技藥品

第12章 市場區隔 - 各地區

第13章 選擇標準

第14章 市場成長推動要素

第15章 推動要素與其影響度

第16章 市場課題

第17章 推動要素與課題的影響度

第18章 市場趨勢

第19章 趨勢與其影響度

第20章 商業環境

  • 競爭情形
    • 重要資訊
    • M&A
  • 市場佔有率分析:2014年
    • F. Hoffmann-La Roche
    • Teva Pharmaceutical Industries
    • Novartis
  • 其他有潛力的企業

第21章 主要供給企業分析 (重要事實、產業概要、產業、各區域銷售額、產業策略、重要資訊、SWOT分析等)

  • F. Hoffmann-La Roche
  • Novartis
  • Teva Pharmaceutical Industries

第22章 系列內的相關報告

目錄
Product Code: IRTNTR6598

About Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia is a malignant condition characterized by increased production of lymphocytes. It has been observed that the cancer first affects B-lymphocytes and then it can spread to other parts of the body. This leukemia is diagnosed mostly at later stages because of the slow buildup of the cancerous cells. During the course of the disease, the malignancy spreads to the spleen, liver, and lymph nodes. The course of the disease is heterogeneous, and prognosis is difficult. Symptoms include swelling of the lymph nodes, fatigue, fever, infection, pain beneath the ribs, and weight loss. Chronic lymphocytic leukemia can be treated with radiation, steroids, chemotherapy, targeted therapy, transplants (bone marrow, stem cell), and surgical procedure to remove the spleen (splenectomy).

Technavio's analysts forecast the global chronic lymphocytic leukemia therapeutics market to grow at a CAGR of 18.52% over the period 2014-2019.

Covered in this Report

In this report, Technavio covers the present scenario and growth prospects of the global chronic lymphocytic leukemia therapeutics market for the period 2015-2019. To calculate the market size, we consider revenue generated from the sales of various drugs used in the treatment of chronic lymphocytic leukemia.

Based on the type of molecule, we group the market into two categories:

  • Biologics
  • Small molecules

Based on the route of administration, we group the market into two:

  • Oral
  • Parenteral

This report includes a discussion of the market in the following three regions:

  • Americas: The major countries focused in the Americas are the US, Canada, Mexico, and Brazil
  • EMEA: The major countries in this region are the UK, Germany, Italy, France, Spain and Middle
  • Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
  • APAC: The major countries in this region are Japan, China, Australia, Singapore, South Korea, and India. APAC is a major untapped market with many leading vendors in the global chronic lymphocytic leukemia therapeutics market.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. In addition, it discusses the major drivers and challenges, as well as the key trends.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • F. Hoffmann-La Roche
  • Novartis
  • Teva Pharmaceutical Industries

Other Prominent Vendors

  • Actavis
  • Amgen
  • Aryogen
  • Astellas
  • Bristol-Myers Squibb
  • Eagle Pharmaceuticals
  • Eisai
  • Fresenius Kabi
  • Genmab
  • Gilead Sciences
  • H. Lundbeck
  • Hospira
  • idd biotech
  • Immunomedics
  • Johnson & Johnson
  • Mundipharma
  • Mylan
  • Noxxon
  • Ono Pharmaceutical
  • PDL BioPharma
  • Pfizer
  • Pharmacyclics
  • Regeneron
  • Sagent Pharmaceutical
  • Sanofi
  • SymBio Pharmaceuticals
  • TheraMAB

Key Market Driver

  • Increase in Patient Pool
  • For a full, detailed list, view our report

Key Market Challenge

  • Unknown Disease Etiology
  • For a full, detailed list, view our report

Key Market Trend

  • Strategic Alliances
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Product Profiles

    • 04.1.1. Gazyva/Gazyvaro
    • 04.1.2. MabThera/Rituxan
    • 04.1.3. Arzerra
    • 04.1.4. Treanda

05. Market Research Methodology

  • 05.1. Market Research Process
  • 05.2. Research Methodology

06. Disease Overview

  • 06.1. Understanding the Disease
  • 06.2. Types of Chronic Lymphocytic Leukemia
  • 06.3. Symptoms
  • 06.4. Diagnosis
  • 06.5. Staging
  • 06.6. Epidemiology
  • 06.7. Management
  • 06.8. Economic Burden

07. Introduction

08. Market Landscape

  • 08.1. Market Overview
  • 08.2. Market Size and Forecast
  • 08.3. Five Forces Analysis

09. Pipeline Portfolio

  • 09.1. Key Information on the Major Pipeline Molecules
    • 09.1.1. RG 105 SC Formulation
    • 09.1.2. Obinutuzumab/ Venetoclax
    • 09.1.3. RG 7596 (Polatuzumab vedotin)
    • 09.1.4. RG 7601 (Venetoclax)

10. Market Segmentation by Route of Administration

  • 10.1. Oral
  • 10.2. Parenteral

11. Market Segmentation by Type of Molecule

  • 11.1. Small Molecules
  • 11.2. Biologics

12. Geographical Segmentation

13. Buying Criteria

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

  • 20.1. Competitive Scenario
    • 20.1.1. Key News
    • 20.1.2. Mergers and Acquisitions
  • 20.2. Market Share Analysis 2014
    • 20.2.1. F. Hoffmann-La Roche
    • 20.2.2. Teva Pharmaceutical Industries
    • 20.2.3. Novartis
  • 20.3. Other and Future Prominent Vendors

21. Key Vendor Analysis

  • 21.1. F. Hoffmann-La Roche
    • 21.1.1. Key Facts
    • 21.1.2. Business Overview
    • 21.1.3. Business Segmentation
    • 21.1.4. Business Segmentation by Revenue 2012 and 2013
    • 21.1.5. Sales by Geography
    • 21.1.6. Business Strategy
    • 21.1.7. Key Information
    • 21.1.8. SWOT Analysis
  • 21.2. Novartis
    • 21.2.1. Key Facts
    • 21.2.2. Business Description
    • 21.2.3. Business Segmentation
    • 21.2.4. Revenue by Business Segmentation
    • 21.2.5. Revenue Comparison 2012 and 2013
    • 21.2.6. Sales by Geography
    • 21.2.7. Business Strategy
    • 21.2.8. Key Developments
    • 21.2.9. SWOT Analysis
  • 21.3. Teva Pharmaceutical Industries
    • 21.3.1. Key Facts
    • 21.3.2. Business Overview
    • 21.3.3. Business Segmentation
    • 21.3.4. Revenue by Business Segmentation
    • 21.3.5. Revenue Comparison 2012 and 2013
    • 21.3.6. Revenue Segmentation by Geography
    • 21.3.7. Business Strategy
    • 21.3.8. Key Developments
    • 21.3.9. SWOT Analysis

22. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Snapshot of Chronic Lymphocytic Leukemia
  • Exhibit 3: Type of Chronic Lymphocytic Leukemia
  • Exhibit 4: Major Diagnostic Procedures to Determine Chronic Lymphocytic Leukemia
  • Exhibit 5: Other Diagnostic Procedures to Determine Chronic Lymphocytic Leukemia
  • Exhibit 6: Rai Staging of Chronic Lymphocytic Leukemia
  • Exhibit 7: Binet Staging of Chronic Lymphocytic Leukemia
  • Exhibit 8: Management of Chronic Lymphocytic Leukemia
  • Exhibit 9: Economic Burden of Chronic Lymphocytic Leukemia
  • Exhibit 10: Global Chronic Lymphocytic Leukemia Therapeutics Market 2014-2019 ($ millions)
  • Exhibit 11: Key Takeaways: Global Chronic Lymphocytic Leukemia Therapeutics Market
  • Exhibit 12: Drug Candidates by Stage of Development, in percentage
  • Exhibit 13: Segmentation of Global Chronic Lymphocytic Leukemia Therapeutics Market by Route of Administration
  • Exhibit 14: Segmentation of Global Chronic Lymphocytic Leukemia Therapeutics Market by Type of Molecules
  • Exhibit 15: Segmentation of Global Chronic Lymphocytic Leukemia Therapeutics Market by Geography, 2014
  • Exhibit 16: Drivers of Global Chronic Lymphocytic Leukemia Therapeutics Market
  • Exhibit 17: Challenges of Global Chronic Lymphocytic Leukemia Therapeutics Market
  • Exhibit 18: Trends of Global Chronic Lymphocytic Leukemia Therapeutics Market
  • Exhibit 19: Global Sales and YoY Growth Rate of Rituxan/MabThera 2010-2014 ($ millions)
  • Exhibit 20: Global Sales and YoY Growth Rate of Treanda 2010-2014 ($ millions)
  • Exhibit 21: Global Sales and YoY Growth Rate of Arzerra 2010-2014($ millions)
  • Exhibit 22: Sales and YoY Growth Rate of Arzerra in US 2010-2014 ($ millions)
  • Exhibit 23: Sales and YoY Growth Rate of Arzerra in Europe 2010-2014 ($ millions)
  • Exhibit 24: Region-wise Revenue Comparison of Arzerra 2010-2014 ($ millions)
  • Exhibit 25: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
  • Exhibit 26: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 27: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
  • Exhibit 28: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
  • Exhibit 29: Novartis AG: Business Segmentation
  • Exhibit 30: Novartis AG: Revenue by Business Segmentation 2013
  • Exhibit 31: Novartis AG: Revenue by Business Segmentation 2012 and 2013 ($ millions)
  • Exhibit 32: Novartis AG: Revenue by Geographical Segmentation 2013
  • Exhibit 33: Teva Pharmaceutical Industries Ltd.: Business Segmentation
  • Exhibit 34: Teva Pharmaceutical Industries Ltd.: Revenue by Business Segmentation 2013
  • Exhibit 35: Teva Pharmaceutical Industries Ltd.: Revenue by Business Segmentation 2012 and 2013 ($ millions)
  • Exhibit 36: Teva Pharmaceutical Industries Ltd.: Revenue by Geographical Segmentation 2013
Back to Top